Posted by Michael Wonder on 14 Oct 2021
Drug pricing tug of war expected over CAR-T therapy Kymriah
14 October 2021 - The world’s first CAR-T therapy, Kymriah (tisagenlecleucel), passed the review of a panel at the Health Insurance Review and Assessment Service, the first of multiple steps to get health insurance coverage.
However, its manufacturer Novartis and the health authorities are expected to have gruelling talks to decide the price of the ultra-expensive drug.
